| Literature DB >> 21197089 |
Stuart A Hamilton1, Rebecca McNeil, Bruce W Hollis, Deborah J Davis, Joyce Winkler, Carolina Cook, Gloria Warner, Betty Bivens, Patrick McShane, Carol L Wagner.
Abstract
OBJECTIVE: Determine prevalence of vitamin D deficiency (VDD) in a diverse group of women presenting for obstetrical care at two community health centers in South Carolina at latitude 32°N. METHODS ANDEntities:
Year: 2010 PMID: 21197089 PMCID: PMC3004407 DOI: 10.1155/2010/917428
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 3.257
Sociodemographic and clinical characteristics at time of enrollment, by self-reported race/ethnicity.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| Maternal age* | 25.0 ± 5.4 | 23.9 ± 5.1 | 26.1 ± 5.4 | 25.8 ± 5.7 | 26.8 ± 5.7 | <.001 |
| Gestational age* | 18.5 ± 8.4 | 18.0 ± 8.0 | 19.2 ± 9.0 | 17.7 ± 7.8 | 19.3 ± 8.2 | .49 |
|
| ||||||
|
| ||||||
|
| ||||||
| <High school | 155 (28%) | 43 (16%) | 102 (48%) | 8 (15%) | 2 (8%) | |
| High school | 215 (38%) | 100 (37%) | 90 (42%) | 18 (34%) | 7 (29%) | |
| Some college | 138 (25%) | 101 (38%) | 15 (7%) | 16 (30%) | 6 (25%) | <.001 |
| Assoc. degree or higher | 51 (9%) | 25 (9%) | 6 (3%) | 11 (21%) | 9 (38%) | |
| Employment (yes) | 252 (45%) | 149 (55%) | 68 (32%) | 28 (53%) | 7 (29%) | <.001 |
|
| ||||||
|
| ||||||
|
| ||||||
| None | 203 (36%) | 4 (1%) | 189 (89%) | 3 (6%) | 7 (29%) | |
| Medicaid | 250 (45%) | 207 (77%) | 12 (6%) | 23 (43%) | 8 (33%) | <.001 |
| Private | 106 (19%) | 58 (22%) | 12 (6%) | 27 (51%) | 9 (38%) | |
|
| ||||||
|
| ||||||
|
| ||||||
| (Median, range)** | 9 | 9 | 9 | 9 | 10 | .040 |
|
| ||||||
|
| ||||||
|
| ||||||
| Preterm birth | 41 (7.3%) | 27 (10.0%) | 11 (5.2%) | 2 (3.8%) | 1 (4.2%) | .17 |
| Preeclampsia | 21 (3.8%) | 13 (4.8%) | 5 (2.4%) | 2 (3.8%) | 1 (4.2%) | .48 |
| Gestational diabetes | 15 (2.7%) | 9 (3.4%) | 3 (1.4%) | 2 (3.8%) | 1 (4.2%) | .30 |
| Diabetes Mellitus (type 1 or 2) | 8 (1.4%) | 6 (2.2%) | 2 (0.9%) | 0 | 0 | .64 |
| Chronic hypertension | 21 (3.8%) | 15 (15.6%) | 1 (1.9%) | 3 (1.4%) | 2 (8.3%) | .036 |
| Planned pregnancy | 196 (35%) | 43 (16%) | 121 (57%) | 21 (40%) | 11 (46%) | <.001 |
| Primigravida† | 190 (34.1%) | 98 (36.4%) | 65 (30.7%) | 19 (36.5%) | 8 (33.3%) | .59 |
| BMI ≥ 30† | 174 (31.1%) | 94 (34.9%) | 65 (30%) | 11 (21%) | 4 (17%) | .076 |
|
| ||||||
|
| ||||||
|
| ||||||
| April-May | 79 (14.1%) | 45 (16.7%) | 23 (10.8%) | 7 (13.2%) | 4 (16.7%) | <.0001 |
| June–September | 309 (55.3%) | 127 (47.2%) | 138 (64.8%) | 27 (50.9%) | 17 (70.8%) | |
| October-November | 79 (14.1%) | 32 (11.9%) | 38 (17.8%) | 8 (15.1%) | 1 (4.2%) | |
| December–March | 92 (16.5%) | 65 (24.2%) | 14 (6.6%) | 11 (20.8%) | 2 (8.3%) | |
P-values refer to the comparison between the four racial/ethnic categories reported.
*ANOVA; †Chi-square; **Subjective Health Rating Scale 0 = poor to 10 = excellent.
Figure 1Baseline circulating 25(OH)D levels (ng/mL).
Prevalence of vitamin D deficiency (N, %) according to race/ethnicity.
| Deficiency category | Total cohort | African-American | Hispanic | Caucasian | Other Ethnicities |
|---|---|---|---|---|---|
| <12 ng/mL | 87 (15.8%) | 67 (25.6%) | 13 (6.1%) | 4 (7.5%) | 3 (12.5%) |
| 12–19 ng/mL | 178 (32.2%) | 112 (42.7%) | 53 (24.9%) | 6 (11.3%) | 7 (29.2%) |
| 20–31 ng/mL | 205 (37.1%) | 68 (26.0%) | 101 (47.4%) | 27 (50.9%) | 10 (41.7%) |
| 32+ ng/mL | 82 (14.9%) | 15 (5.7%) | 46 (21.6%) | 16 (30.0%) | 4 (16.7%) |
Serum 25(OH)D and PTH according to gestational age.
| <15 6/7 weeks | 16–27 6/7 weeks | 28+ weeks |
| |
|---|---|---|---|---|
| 25(OH)D (ng/mL) | 21.9 ± 9.7 | 21.2 ± 9.1 | 22.2 ± 10.7 | .83 |
| Median (range) | 20.5 (4.2–73.8) | 20.4 (5.1–44.1) | 20.4 (3.8–61.3) | |
| PTH (pg/mL)* | 16.9 ± 7.2 | 21.3 ± 9.0 | 23.9 ± 10.6 | <.001 |
| Median (range) | 15.7 (4.7–39.5) | 20.2 (5.8–48.0) | 22.4 (6.6–70.8) |
Reported as mean (SD) in row 1, and median (range) in row 2. *Missing data (n = 1) for PTH.
Multinomial logistic regression model for the univariate associations between vitamin D concentration and age, gravidity, BMI, race, and season of measurement.
| Variable | Vitamin D group | Odds ratio | 95% CI |
|
|---|---|---|---|---|
| Age < 25 | <20 | 1.35 | 0.82–2.21 | .24 |
| 20–31 | 1.28 | 0.77–2.14 | .35 | |
| 32+ | 1.00 (ref) | — | — | |
|
| ||||
| Primigravida | <20 | 0.82 | 0.49–1.38 | .45 |
| 20–31 | 0.99 | 0.58–1.71 | .99 | |
| 32+ | 1.00 (ref) | — | — | |
|
| ||||
| Obesity (BMI ≥ 30) | <20 | 2.19 | 1.23–3.90 | .008 |
| 20–31 | 1.21 | 0.66–2.22 | .54 | |
| 32+ | 1.00 (ref) | — | — | |
|
| ||||
| African-American (versus Caucasian) | <20 | 20.28 | 7.91–52.02 | <.0001 |
| 20–31 | 2.96 | 1.29–6.78 | .007 | |
| 32+ | 1.00 (ref) | — | — | |
|
| ||||
| Hispanic (versus Caucasian) | <20 | 2.44 | 1.03–5.81 | .046 |
| 20–31 | 1.44 | 0.71–2.90 | .51 | |
| 32+ | 1.00 (ref) | — | — | |
|
| ||||
| Summer Months | <20 | 0.60 | 0.34–1.05 | .073 |
| 20–31 | 0.88 | 0.49–1.59 | .67 | |
| 32+ | 1.00 (ref) | — | — | |
Odds ratios are univariate (unadjusted for the other listed covariates); no additional covariates were included in the model. Vitamin D group sample sizes are as follows: <20, n = 265; 20–31, n = 205; 32+, n = 82. Missing data were as follows: gravidity (n = 2). The race category of “Other” was excluded from this analysis due to small sample size.
History of prior or current medical conditions of study participants and 25(OH)D concentrations at time of enrollment.
| Medical condition |
| 25(OH)D Concentration of those | 25(OH)D Concentration of those |
|
|---|---|---|---|---|
| Urinary tract infection | 160 (28.6%) | 20.7 (8.9) | 21.7 (10.3) | .27 |
| Abnormal PAP smear | 92 (16.5%) | 21.0 (11.5) | 21.5 (9.6) | .62 |
| History of preterm labor or miscarriage | 41 (7.3%) | 18.3 (11.2) | 21.7 (9.8) | .039* |
| Anemia | 47 (8.4%) | 19.5 (7.1) | 21.6 (10.2) | .16 |
| Asthma | 45 (8.1%) | 19.6 (8.3) | 21.6 (10.1) | .21 |
| Psychiatric illness | 36 (6.4%) | 19.5 (8.1) | 21.6 (10.1) | .23 |
| Bipolar disorder | 5 (0.9%) | 23.2 (10.2) | 21.4 (10.0) | .68 |
| Depression | 29 (5.2%) | 19.5 (8.1) | 21.5 (10.0) | .29 |
| Varicose veins | 23 (4.1%) | 25.3 (13.4) | 21.3 (9.8) | .056 |
| Hypertension | 21 (3.8%) | 17.3 (10.9) | 21.6 (9.9) | .055 |
| Kidney stones and/or disease | 10 (1.8%) | 21.7 (6.4) | 21.4 (10.0) | .93 |
| Diabetes | 8 (1.4%) | 13.5 (4.5) | 21.5 (10.0) | .023* |
| Seizures | 7 (1.3%) | 19.5 (8.0) | 21.5 (10.0) | .61 |
| Tuberculosis | 6 (1.1%) | 22.4 (5.8) | 21.4 (10.0) | .81 |
| Thyroid disease | 5 (0.9%) | 19.8 (11.5) | 21.4 (10.0) | .71 |
| Any Reported Sexually Transmitted Disease | 126 (22.5%) | 18.3 (9.4) | 22.3 (9.9) | <.001* |
| Chlamydia | 99 (17.7%) | 18.2 (9.8) | 22.1 (9.9) | .0003* |
| Gonorrhea | 29 (5.2%) | 19.6 (7.8) | 21.5 (10.1) | .32 |
| Genital herpes | 11 (2.0%) | 18.1 (9.7) | 21.5 (10.0) | .26 |
| Genital warts | 10 (1.8%) | 19.2 (5.7) | 21.5 (10.0) | .48 |
Figure 2Scatterplot of PTH and 25(OH)D concentrations. The overlaid line modeling the relationship between PTH and 25(OH)D was fit using loess regression (locally weighted smoothed regression).
(a) Estimated PTH (pg/mL) levels for each category of self-identified race and ethnicity†
|
| Mean (SD) | Range | |
|---|---|---|---|
| All participants | 551 | 19.2 (8.8) | 4.7–70.8 |
| African-American | 261 | 19.6 (9.5) | 5.1–70.8 |
| Caucasian | 53 | 17.9 (9.1) | 6.2–38.7 |
| Hispanic | 213 | 19.1 (8.0) | 4.7–40.9 |
| Other | 24 | 18.0 (6.6) | 7.6–32.6 |
†Eight subjects had insufficient blood sample to measure PTH and thus, were excluded from this table.
(b) Serum PTH (pg/mL) according to gestational age and race/ethnicity**
| PTH According to Gestational Age and Race/Ethnicity | |||
|---|---|---|---|
| <32 weeks | 32–35 weeks | 36+ weeks | |
| All participants | 18.7 (8.5) | 21.5 (9.1) | 26.9 (9.6) |
| African-American | 19.0 (9.0) | 22.0 (10.9) | 32.9 (9.8) |
| Caucasian | 17.6 (8.8) | 20.3 (9.5) | 27.8 (—) |
| Hispanic | 18.5 (8.0) | 22.6 (7.0) | 23.1 (7.5) |
| Other | 18.5 (6.5) | 11.8 (—) | |
**Reported as mean (SD) in row 1 and median (range) in row 2. Blank cells are those that contain no participants. SD was not estimated in cells that contain fewer than 3 observations.